‘The undruggable became druggable’: a gamechanging treatment for the world’s deadliest cancer
About this episode
A new daily pill, daraxonrasib, has shown to double survival time for patients with the world's deadliest cancer, marking a significant breakthrough in treatment.
A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a gamechanger and one of the biggest breakthroughs in decades. To find out more about how daraxonrasib works and how life-changing it could be for patients, Madeleine Finlay speaks to Prof Naureen Starling, consultant medical oncologist at the Royal Marsden hospital. Help support our independent journalism at theguardian.com/sciencepod
More episodes of Science Weekly
- The dinosaurs who survived the asteroid
- Heatstroke, sports washing and VAR psychology: the science of the World Cup
- The incredible science of the sleeping brain
- Are robots nearing their ChatGPT moment?
- Red-light masks: can they really slow ageing?
- Stateside with Kai and Carter: why the fight over abortion pills is only just beginning
Explore listener stats, chart rankings, contacts and more on the Science Weekly podcast page.